

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AIM Vaccine Co., Ltd.**

**艾美疫苗股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 06660)**

**VOLUNTARY ANNOUNCEMENT  
INITIATION OF PHASE II CLINICAL TRIAL OF  
TETRAVALENT MENINGOCOCCAL CONJUGATE VACCINE**

This announcement is made by AIM Vaccine Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that on March 2, 2024, the randomized, blinded and comparable vaccine-controlled Phase II clinical trial of the Group’s tetravalent meningococcal conjugate vaccine (MCV4) was officially initiated, with the Yunnan Provincial Center for Disease Control and Prevention as the responsible institution, and the Center for Disease Control and Prevention of Longyang District, Baoshan and the Center for Disease Control and Prevention of Weishan Yi and Hui Autonomous County, Dali Prefecture as the research sites.

Epidemic cerebrospinal meningitis (hereinafter referred to as meningococcal disease) is a bacterial vaccine-preventable acute infectious disease caused by *Neisseria meningitidis*, with meningitis and sepsis as the clinical manifestations. The disease is widely distributed, has an acute onset, rapid progression, high infectivity, high latent infection rate and high mortality rate, and could cause serious harm. In the World Health Organization’s grading of vaccine-preventable diseases, meningococcal series products are at a high priority level. The Group’s MCV4 can prevent epidemic cerebrospinal meningitis caused by Group A, C, Y and W135 *Neisseria meningitidis*, and other invasive diseases.

To date, the Group has completed the construction of the production workshop for the MCV4. The product will have a promising market prospect after being marketed. In 2023, the global sales of meningococcal conjugate vaccine products reached approximately US\$1.418 billion. In the future, both of the Company's two meningococcal vaccines will contribute to the control of meningococcal diseases in China.

By order of the Board  
**AIM Vaccine Co., Ltd.**

**Mr. Yan ZHOU**

*Chairman of the Board, Executive Director  
and Chief Executive Officer*

Hong Kong, March 4, 2024

*As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.*